{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:50:12Z","timestamp":1774543812877,"version":"3.50.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A retrospective descriptive cohort study was performed using data from the British Association of Dermatologists Biologics and Immunomodulator Register, a registry pharmacovigilance study in the UK and Ireland looking at people with a diagnosis of psoriasis. There was no statistically significant association between methotrexate (MTX) exposure and fibrotic interstitial lung disease (fILD) occurrence. Among people exposed to MTX for psoriasis, there were 2.5 fewer fibrosis cases per 10 000 person-years compared with the nonexposed group. These findings are consistent with the evolving body of evidence challenging the perceived link between MTX exposure and development of fILD and support that chest radiography is probably unnecessary in dermatology drug monitoring clinics.<\/jats:p>","DOI":"10.1093\/ced\/llaf553","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:57:35Z","timestamp":1765630655000},"page":"634-637","source":"Crossref","is-referenced-by-count":0,"title":["Fibrotic interstitial lung disease in patients with psoriasis using methotrexate: a descriptive cohort study using British Association of Dermatologists Biologics and Immunomodulator registry data"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-0975","authenticated-orcid":false,"given":"Eleanor","family":"Clarke","sequence":"first","affiliation":[{"name":"Department of Dermatology, Portsmouth University Hospitals NHS Trust , St Marys Hospital, Portsmouth ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-9017","authenticated-orcid":false,"given":"Birgitta","family":"van Bodegraven","sequence":"additional","affiliation":[{"name":"Department of Research and Publishing, British Association of Dermatologists , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa R","family":"Shipman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Portsmouth University Hospitals NHS Trust , St Marys Hospital, Portsmouth ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026032611540153500_llaf553-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur Respir Rev"},{"key":"2026032611540153500_llaf553-B2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/rheumatology\/41.3.262","article-title":"Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests","volume":"41","author":"Dawson","year":"2002","journal-title":"Rheumatology"},{"key":"2026032611540153500_llaf553-B3","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2026032611540153500_llaf553-B4","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"2026032611540153500_llaf553-B5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026032611540153500_llaf553-B6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00296-020-04773-4","article-title":"Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review","volume":"41","author":"Dawson","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026032611540153500_llaf553-B7","doi-asserted-by":"crossref","first-page":"h1269","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","author":"Conway","year":"2015","journal-title":"BMJ"},{"key":"2026032611540153500_llaf553-B8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026032611540153500_llaf553-B9","first-page":"370","article-title":"Interstitial pneumonia in psoriasis","volume":"2","author":"Kawamoto","year":"2018","journal-title":"Mayo Clin Proc Innov"},{"key":"2026032611540153500_llaf553-B10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12931-024-02721-5","article-title":"Psoriasis may increase the risk of idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study","volume":"25","author":"Chen","year":"2024","journal-title":"Respir Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf553\/65882824\/llaf553.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/634\/65882824\/llaf553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/634\/65882824\/llaf553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:54:06Z","timestamp":1774540446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/4\/634\/8380001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf553","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,15]]}}}